Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382650 · ClinicalTrials.gov registry record
Survey of Human Rabies Immune Globulin Safety in Children
A clinical trial, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- 35
- Enrollment target
NCT05382650 is a clinical trial that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 35 participants.
The verdict
NCT05382650 was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- 35 participants
- Enrollment target
Study Summary
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.
Interventions
- BIOLOGICAL Human rabies immune globulin 300 IU/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2025-10-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05382650
The ClinicalTrials.gov registry entry for NCT05382650 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human rabies immune globulin 300 IU/mL is the first listed.
NCT05382650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05382650 about?
NCT05382650 is a clinical study titled "Survey of Human Rabies Immune Globulin Safety in Children". This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric pa...
What is the current status of trial NCT05382650?
This trial is currently terminated. The enrollment target is 35 participants. The study started on 2023-02-22. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT05382650?
The interventions under investigation include: Human rabies immune globulin 300 IU/mL (BIOLOGICAL).
Who is sponsoring clinical trial NCT05382650?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.